Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States
Tóm tắt
Clinical guidelines generally recommend endocrine therapy over chemotherapy for hormone receptor-positive advanced breast cancer (unless life-threatening metastases are present). This study aimed to assess the real-world treatment patterns of patients with hormone receptor-positive advanced breast cancer in Europe and the United States. Treatment patterns in Europe (France, Germany, Italy, Spain, and the UK) and the United States from January 2012 to December 2014 were investigated using a patient record database (Global Oncology Monitor©). Sample data were projected to the wider clinical population to provide running annual estimates every 3 months. Sample sizes ranged from 1272 to 1640 patients in Europe and from 2225 to 2760 patients in the United States. Across all lines of therapy, 37–43% (Europe) and 45–50% (United States) of patients received chemotherapy. More patients received endocrine therapy than chemotherapy as first-line treatment for advanced breast cancer (Europe: 51–54% vs. 33–35%; United States: 53–60% vs. 34–42%). In contrast, endocrine therapy-only regimens were given less commonly than chemotherapy-only regimens in the third-line setting in both Europe and the United States. Chemotherapy is used extensively in routine clinical practice for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. The results also suggest that the treatment patternsin Europe and the United States are qualitatively different.
Funding: Ipsos Healthcare and AstraZeneca.
Tài liệu tham khảo
Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014;25:1871–88.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Version 2.2015: Breast Cancer. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed July 23, 2016.
Sainsbury R. The development of endocrine therapy for women with breast cancer. Cancer Treat Rev. 2013;39:507–17.
Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2−) breast cancer patients in the United States: 2002–2012. Curr Med Res Opin. 2014;30:1537–45.
European Medicines Agency. Everolimus approval. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/001038/WC500129092.pdf. Accessed July 23, 2016.
US Food and Drugs Administration. Everolimus approval. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm313008.htm. Accessed July 23, 2016.
Andre F, Neven P, Marinsek N, et al. Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Curr Med Res Opin. 2014;30:1007–16.
Macalalad AR, Hao Y, Lin PL, et al. Treatment patterns and duration in post-menopausal women with HR+/HER2− metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004–2010). Curr Med Res Opin. 2015;31:263–73.